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Memory CD8+ T cells proliferate faster than naive cells to rapidly control an infectious challenge, but West
et al. (2011) in this issue of Immunity report that this superiority is lost in the face of a high dose or chronic
viral challenge.For a period of time in the 1990s, Rolf
Zinkernagel was fond of stirring up audi-
ences by questioning the role of immuno-
logical memory. If the immune system
doesn’t win the battle with the pathogen
the first time around, he argued, there is
no need for memory because you’re
dead. If it does win the battle, then you
don’t need memory because you can
cope with the pathogen without it. The
argument was meant to provoke, and it
generally succeeded. In the current issue
of Immunity, West et al. (2011) do some
stirring of their own, challenging the notion
that memory T cells are always better than
naive cells at their job.
Intense study of T cell memory over
the past two decades has yielded a lot
of knowledge about this quintessential
immunological process (Harty and Bado-
vinac, 2008; Kaech and Wherry, 2007;
Williams and Bevan, 2007; Jameson and
Masopust, 2009). Memory T cells are
well known to deal with an acute infection
more efficiently than naive ones. On a per
cell basis, they proliferate faster, develop
effector functions more quickly, and traf-
fic to infected tissue sooner than their
naive counterparts. However, West et al.
(2011) were specifically concerned with
the challenge of making vaccines that
can protect against chronic pathogens
such as HIV and hepatitis C virus. Immu-
nity against these pathogens is frequently
compromised by the phenomenon known
as T cell exhaustion, where T cells decline
in numbers and lose functional capacity. If
vaccination is to succeed, the memory
T cell population needs to do a better
job. How do memory and naive T com-
pare in that setting?
The term ‘‘exhaustion’’ was initially
coined to describe the phenomenon of
dysfunction and deletion in the face of158 Immunity 35, August 26, 2011 ª2011 Elschronic virus infection with a high anti-
genic burden (Moskophidis et al., 1993;
Shin and Wherry, 2007). It is evocative of
heroic battlefield efforts in the face of
overwhelming odds: ‘‘they fell with their
faces to the foe.’’ It is interesting to note
that similar processes in other fields of
immunology may be given names with
different connotations: immunosuppres-
sion in tumor immunology and tolerance
in the field of transplantation. However,
although the term ‘‘exhaustion’’ is still
used in infectious disease immunology, it
is not considered to reflect absolute loss
of capacity. Exhausted T cells express
inhibitory receptors such as PD-1 and
can be rescued from their exhaustion by
several different manipulations, including
blockade of PD1 (Barber et al., 2006).
Importantly, the rejuvenated CD8+ T cells
are effective in reducing virus load. With
their eyes on the long-term goal of vacci-
nating against chronic diseases, West
et al. (2011) asked how memory T cells,
generated either by vaccination or low-
dose infection, would perform when
challenged with a high-dose lymphocytic
choriomenengitis virus (LCMV) clone-13,
a model of chronic infection.
In order to fairly compare naive and
memory T cells, the investigators adop-
tively transferred equal numbers of naive
and memory P14 CD8+ T cells, which
express a T cell receptor (TCR) specific
for an LCMV glycoprotein epitope, into
naive recipients. This experimental strat-
egy ensured that the naive and memory
CD8+ T cells had equal TCR affinity and
were exposed to the same amount of viral
antigen, cytokines, etc. As expected,
when challenged by a controllable ‘‘acute’’
infection (either Armstrong strain or low-
dose clone-13 strain LCMV), memory cells
dominated the playing field. They prolifer-evier Inc.ated more from the outset than their naive
counterparts, achieved numerical domi-
nance in thefirst fewdays,andhadbrought
the infection under control by the time the
new recruits were ready to join the battle.
The surprising finding came when the
recipient mice were challenged with a
high dose (2 million pfu) of clone-13. Not
only did memory T cells fail to control the
high-dose challenge, they were overtaken
by their naive colleagues. Naive T cells
proliferated far more, with the result that
a week after infection, primary effectors
(progeny of the naive transferred cells) out-
numbered thememory-derived secondary
effectors by approximately 10:1. The naive
cells were considered to have outper-
formed their seasoned comrades, and
they obviously did so if the measure of
performance is sticking around in the face
of an overwhelming antigen load (Figure 1).
However, if judged by their ability to
impact virus load, the memory cells don’t
appear quite so shoddy. West et al.
(2011) compared the ability of 3 3 104
naive and memory cells to control clone-
13 challenge across a range of doses
from 200 to 2 million pfu. Memory cells
reduced viral titers far more sharply than
naive cells at lower challenge doses, but
seemed to reacha ‘‘tippingpoint’’ at about
105 pfu: beyond this dose, neither trans-
ferred population had any impact on virus
load through the first week of infection.
However, increasing the number of trans-
ferred P14 cells tilted the balance back in
the T cells’ favor: 105 memory P14 cells
could control virus titers after even 106
pfu challenge dose; it took more than
twice asmany naive cells to have a similar
impact. Eventually, though, the enhanced
staying power of the primary effectors
may yield a small benefit. In a supplemen-
tary figure, West et al. (2011) show that at
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Figure 1. Contrasting Behavior of the Progeny of Naive and Central Memory T Cells in
Response to Acute or Chronic LCMV Infection
Left: in response to a controllable, acute LCMV infection, memory T cells proliferate more rapidly than
naive precursors and dominate the response. Virus is efficiently eradicated because of the rapid effector
functions of the secondary effectors. Right: When challenged with a high-dose clone-13 infection, both
precursor types respond initially but fail to bring virus titers down. Primary and secondary effector popu-
lations both express inhibitory receptors, depicted in the cartoon as white flags, and become exhausted in
the face of persistent high virus titers. Secondary effectors are further inhibited by higher expression of
2B4 and by a unique reliance on CD4+ T cell help. As a consequence, they proliferate less than primary
effectors from very early time points of the challenge and persist at a 1/10 the numbers.
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Previews14 days after infection, virus titers were
slightly but significantly lower in mice
that had received the naive cell transfer.
The virus control experiments contain
a key message of this paper for vaccine
development: memory T cells are great,
even against a chronic pathogen, if they
can establish early control. It’s all a num-
bers game. Presumably, a sufficient nu-
merical advantage precludes the frequent
T cell activation events that trigger ex-
haustion. And in real life there will always
be more memory than naive T cells: in-
creased frequency of antigen-specific cells
is a cardinal feature of immunological
memory. We should not forget that the
experiments in this study deliberately re-
moved the numerical advantage of mem-
ory inorder toaskaspecificscientificques-
tion. To vaccinate effectively against these
difficult, chronicpathogens,a largenumber
of memory cells and the ability to gain early
control is crucial. This is reminiscent of the
argument made by Louis Picker in explain-
ing the success of his CMV-vectored SIV
vaccine (Hansen et al., 2011), although inthat model, effector memory cells were
important for early control.
West et al. (2011) performed more
experiments to dissect the mechanisms
underlying the different behaviors of naive
and memory-derived effectors, and these
also yielded important insights. Transcrip-
tional profiling of primary and secondary
effectors in the chronic phase revealed
that both populations expressed inhibi-
tory receptors, consistent with the ex-
hausted phenotype of both populations.
However, secondary effectors expressed
a lot more of the 2B4 receptor. Quite re-
markably, genetic deletion of 2B4 re-
versed thememory cells’ disadvantage vis
a` vis naive cells during chronic infection.
Evenmore remarkable was the dramatic
rescueofsecondaryeffectorTcell numbers
achieved by supplying antigen-specific
CD4+ T cell help. Admittedly, this help was
provided by transferring 500 LCMV-
specific CD4+ T cells for each CD8+ T cell,
which was hardly physiological. However,
CD4+ T cell help gave the secondary effec-
tors an enormous boost, while having noImmunity 35impact on primary effectors. Again, this
indicates a differential programming be-
tween the twopopulations. It alsohighlights
the need to pay attention to the CD4
response in vaccine strategies.
It is hard to resist the temptation to
speculate about why naive and memory
cells are subject to differential regulation.
West et al. (2011) discuss twopossibilities:
memory cells may be more tightly regu-
lated to limit their potential for immunopa-
thology, or theymay simplybemorediffer-
entiated, lacking thecapacity toproliferate
as much. There is a good basis for the
capacity theory: T cells apparently do not
have a limitless capacity for division,
and with more divisions in their history,
memory cells may be closer to true repli-
cative senescence (Harty and Badovinac,
2008). However, it is interesting that
memory cells didn’t just fail to divide in
chronic clone-13 infection, they displayed
analteredpredisposition toexhaustion, by
increased 2B4 expression and depen-
dency onCD4+ T cell help.When provided
with CD4+ T cell help, they displayed
remarkable proliferative capacity.
The other theory suggested by West
et al. (2011) concerns immunopathology.
This is a real concern for the immune
system. CD8+ T cells are loaded with
potent effector molecules and can release
a fatal cytokine storm. Less dramatically,
the resource commitment tomaintaining a
large immune response must be weighed
against the actual damage caused by the
invader. At all times the immune system is
following algorithms that integrate mul-
tiple sources of information to assess
the real degree of danger and tomount re-
sponses accordingly. Large resource ex-
penditure and immunopathology should
be risked only if the danger is commensu-
rate. Perhaps this idea is along similar
lines of reasoning to Rolf Zinkernagel,
when he argued that an infection that
didn’t kill the first time around might not
warrant toomuch fuss. Only memory cells
know that a previous encounter was
survived, and perhaps their programming
allows for an earlier retreat.REFERENCES
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